Clinical trials
Adenovirus clinical trials
Below are recruiting adenovirus clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07359235RecruitingPhase 1
KD01 for bladder cancer: a safety and early efficacy trial
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
Wuhan, HubeiAges 18–75 - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT02455479RecruitingPhase 1
Safety study of a vaccine for cocaine dependence
This early-stage study tests how safe an experimental “cocaine vaccine” is and how the body reacts to it. You must also be in behavioral therapy, and the study aims to see whether the vaccine can be given safely to people with cocaine use disorder.
New York, New YorkAges 21–69 - NCT03159364RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests whether specially grown immune cells (T cells) can fight common viruses like CMV, EBV, or BK virus in people with weakened immune systems, such as after a stem cell or organ transplant. It may help when standard medicines don't work or can't be used.
Shenzhen, GuangdongAges 6 months–80 years - NCT07625423RecruitingPhase 1
Gene therapy injection for advanced head and neck cancer
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
Chengdu, ChinaAges 18–65 - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years
Hear when a new Adenovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adenovirus?
- Yes. Clin2 currently lists 31 recruiting adenovirus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adenovirus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adenovirus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.